These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 37140558)
1. Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial. López P; López-Medina E; Sáez-Llorens X; deAntonio R; Masuda T; Mendelman PM; Sherwood J; Baehner F; Borkowski A Hum Vaccin Immunother; 2023 Dec; 19(1):2204787. PubMed ID: 37140558 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study. Vesikari T; Saez-Llorens X; Blazevic V; Lopez P; Lopez E; Masuda T; Mendelman PM; Liu M; Sherwood J; Baehner F; Borkowski A Vaccine; 2022 Jun; 40(26):3588-3596. PubMed ID: 35595661 [TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose. Treanor J; Sherwood J; Cramer JP; Le Cam Bouveret N; Lin S; Baehner F; Borkowski A; Vaccine; 2020 Aug; 38(36):5842-5850. PubMed ID: 32563606 [TBL] [Abstract][Full Text] [Related]
5. Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. Leroux-Roels G; Cramer JP; Mendelman PM; Sherwood J; Clemens R; Aerssens A; De Coster I; Borkowski A; Baehner F; Van Damme P J Infect Dis; 2018 Jan; 217(4):597-607. PubMed ID: 29140444 [TBL] [Abstract][Full Text] [Related]
6. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. Treanor JJ; Atmar RL; Frey SE; Gormley R; Chen WH; Ferreira J; Goodwin R; Borkowski A; Clemens R; Mendelman PM J Infect Dis; 2014 Dec; 210(11):1763-71. PubMed ID: 24951828 [TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine. Leroux-Roels I; Maes C; Joye J; Jacobs B; Jarczowski F; Diessner A; Janssens Y; Waerlop G; Tamminen K; Heinimäki S; Blazevic V; Leroux-Roels G; Klimyuk V; Adachi H; Hiruta K; Thieme F Front Immunol; 2022; 13():1021500. PubMed ID: 36275772 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults. Sherwood J; Mendelman PM; Lloyd E; Liu M; Boslego J; Borkowski A; Jackson A; Faix D; Vaccine; 2020 Sep; 38(41):6442-6449. PubMed ID: 32878708 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial. Li J; Shi LW; Yu BW; Huang LR; Zhou LY; Shi L; Jiang ZW; Xia JL; Wang XY; Li RC; Yuan L; Li YP; Li CG Vaccine; 2023 May; 41(19):3141-3149. PubMed ID: 37061370 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R; Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial. Han HH; Diaz C; Acosta CJ; Liu M; Borkowski A Lancet Infect Dis; 2021 Sep; 21(9):1282-1292. PubMed ID: 34019802 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638 [TBL] [Abstract][Full Text] [Related]
15. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793 [TBL] [Abstract][Full Text] [Related]